Sysmex and QIAGEN Expand Collaboration in Genetic Testing

Sysmex Corporation (Kobe, Japan) has expanded its strategic alliance agreement with QIAGEN N.V. (Venlo, The Netherlands) to deepen their cooperation in genetic testing, encompassing areas such as research and development, manufacturing, clinical development, and sales-marketing.

Sysmex has been a significant player in the in vitro diagnostics arena for over five decades, continually advancing its genetic testing capabilities. A key aspect of this advancement is the deployment of liquid biopsy technologies in product development to deliver personalized medicine solutions to both patients and healthcare professionals. With a robust global sales and service network backed by premier laboratories in Japan and the USA, Sysmex is dedicated to furthering the innovation of diagnostic technologies and high-value testing. Meanwhile, QIAGEN stands as a leader in precision medicine and a primary partner for pharmaceutical and biotech companies, developing companion diagnostics that identify genetic variances to inform clinical treatment decisions. QIAGEN’s technological suite ranges from polymerase chain reaction (PCR), multiplex PCR, digital PCR (dPCR), to next-generation sequencing (NGS), offering tailored solutions to over 30 global pharmaceutical partners through master collaboration agreements.

Since their initial alliance in 2013 and their decision to forge a strategic partnership for companion diagnostics in 2021, Sysmex and QIAGEN have seen considerable collaborative success. With the recent expansion of this partnership, the companies aim to leverage their combined expertise in genetic testing to produce high-value offerings for their global clientele. Under the new terms, Sysmex will integrate QIAGEN’s assays into the clinical trials it conducts for pharmaceutical companies and research institutions across its global network of laboratories, enhancing QIAGEN's global service capabilities.